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We investigated the mode of action underlying the anti-mycoplasma activity of cationic
antimicrobial peptides (AMPs) using four known AMPs andMycoplasma pulmonis as a model myco-
plasma. Scanning electron microscopy revealed that the integrity of theM. pulmonismembrane was
signiﬁcantly damaged within 30 min of AMPs exposure, which was conﬁrmed by measuring the
uptake of propidium iodine into the mycoplasma cells. The anti-mycoplasma activity of AMPs was
found to depend on the binding afﬁnity for phosphatidylcholine, which was incorporated into the
mycoplasma membrane from the growth medium and preferentially distributed in the outer leaﬂet
of the lipid bilayer.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction immune evasion and virulence of mycoplasmas [5,6]. Indeed,Mycoplasmas, which are the smallest self-replicating organisms
in nature, have become one of the major concerns in human and
veterinary medicine since they are known to be etiological agents
for a variety of infectious diseases [1]. Although they are descen-
dents of Gram-positive bacteria, mycoplasmas have many peculiar
features that differ distinctly from cell wall synthesizing bacteria
[2]. For example, they lack a rigid cell wall and are bound by a sin-
gle plasma membrane that interacts directly with their environ-
ment. Additionally, most mycoplasmas strictly require host
sterols and are generally cultured in serum-containing medium
that supplies the choline-containing phospholipids, phosphatidyl-
choline (PC) and sphingomyelin (SPM), which are incorporated into
the plasma membrane of the mycoplasma [3,4]. It has been
postulated that these two phospholipids are involved in themicrobial cell surface components such as peptidoglycans,
lipopolysaccharides, lipoteichoic acid, mannan and b-glucan are
major target molecules in the recognition of microbial pathogens
by the host defense system [7]. Accordingly, it is important to
elucidate how the wall-less mycoplasmas interact with host
defense systems.
Over the last three decades, cationic antimicrobial peptides
(AMP) have been shown to play pivotal roles in defense systems
of animals ranging from insects to humans [8]. AMPs are capable
of directly killing microbial pathogens and/or modulating host de-
fense reactions to cope with invading microbes [8]. To exert their
antimicrobial effects, AMPs interact with unique molecular
patterns on the surface of pathogens. It is well known that most
cationic AMPs recognize microbes via their speciﬁc binding to an-
ionic components occurring in the cell wall of bacteria and fungi
[9]. However, it is not known how they recognize and kill myco-
plasmas without cell walls. To date, there have been a few studies
conducted to investigate the anti-mycoplasma activity of cationic
AMPs although no attempts to demonstrate the mode of action
underlying their anti-mycoplasma potency [10–12]. The studies
showed that the anti-mycoplasma activity of AMPs was not in
accordance with their antimicrobial activity against bacteria
equipped with cell walls [11,12]. These ﬁndings suggest that AMPs
exert an anti-mycoplasma activity in a fashion that differs from
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are generally mediated by binding to components of the microbial
cell wall.
In this study, we evaluated the anti-mycoplasma activity of four
known cationic AMPs: HG1, LL-37, MSI-78 and polymyxin B [13–
16]. In addition, we conducted diverse experiments in an attempt
to elucidate the mechanism of AMPs against mycoplasmas using
Mycoplasma pulmonis as a model mycoplasma. This study is the
ﬁrst to shed light on the mode of action by which cationic AMPs kill
mycoplasmas.2. Materials and methods
2.1. Peptides and reagents
Three AMPs (HG1, LL-37 and MSI-78) used in this study were
synthesized using an automated solid-phase peptide synthesizer
(Pioneer Applied Biosystems, USA) at Peptron, Inc. (Daejon, Korea),
and then puriﬁed to over 95% with a C18 reversed-phase HPLC
column (Vydac 218TP54: The Separation Group, Hesperia, USA).
Polymyxin B (81334) and kanamycin (K1876) were purchased
from Sigma. In addition, four phospholipids were also purchased
from Sigma: 1-palmytoyl-2-oleoyl L-a-phosphatidylcholine (POPC,
P3556), 1-palmytoyl-2-oleoyl L-a-phosphatidylglycerol (POPG,
P8318), cardiolipin (CL, C0563), and sphingomyelin (SPM, S0756).
2.2. Mycoplasma strains and culture medium
The mycoplasmas were grown in PPLO broth (Difco, 255420)
supplemented with 10% (v/v) horse serum (GIBCO, 16050-122),
yeast extract, glucose, ampicillin and phenol red at 30 C. The pH
of the medium was adjusted to 7.8. To prepare PPLO agar plates,
the broth was supplemented with 1% bacto agar (Difco, 214010)
without phenol red. Wild-type M. pulmonis strain CT and its two
mutants (M. pulmonis CTG1701 and CTG2028) were used as models
to investigate the interaction between mycoplasmas and AMPs.
CTG1701 and CTG2028 strains are exopolysaccharide (EPS) mu-
tants that have a long variable surface antigen (Vsa) and an inter-
mediate-length Vsa protein, respectively [17].
2.3. Scanning electron microscopy (SEM)
WashedM. pulmonis (109 CFU) were incubated with three AMPs
(HG1, 16 lg/ml; LL-37, 32 lg/ml; MSI-78, 64 lg/ml) or kanamycin
(2 lg/ml) at 37 C for 30 min and 3 h, respectively. Additionally,
one sample was incubated with only 10 mM sodium phosphate
(NaP) buffer (pH 7.4) as a control. Each sample was then washed
three times with NaP buffer, after which the cells were ﬁxed for
6 h in 50 mM sodium cacodylate buffer (pH 7.2) containing 2% glu-
taraldehyde and 2% paraformaldehyde. The ﬁxed cells were subse-
quently washed extensively with 50 mM sodium cacodylate and
then dehydrated with a graded series of ethanol concentrations
(50%, 70%, 90%, 95%, 100%  2). A drop of each sample in 100% eth-
anol on a slide was then subjected to critical-point drying, after
which the cells were coated with gold–palladium. Micrographs
were obtained using a Quanta FEG 200 scanning electron micro-
scope (FEI, Netherlands).
2.4. Propidium iodone (PI) uptake assay
M. pulmonis cells were washed and suspended in NaP buffer at
109 CFU/ml. Next, 100 ll aliquots of the stock sample were dis-
pensed into each well of a 96-well ﬂuorescence assay plate (SPL,
30196). To pre-stain the cells, 5 ll of PI (SIGMA, P4170) was added
into each well to a ﬁnal concentration of 5 lM and the sample wasincubated for 15 min in the dark. Peptide or kanamycin was then
added into each well to give a ﬁnal concentration of 16 lg/ml. At
the predetermined time, the ﬂuorescence intensity of each mixture
was measured using a microplate reader (BioTek Laboratory
Instruments, USA) with excitation and emission values of 530
and 620 nm, respectively. For a positive control (100% PI uptake),
the sample was treated with 1% (v/v) Triton X-100 instead of pep-
tides or kanamycin.
2.5. Two-dimensional thin layer chromatography (TLC)
Membrane lipids of M. pulmonis CT were extracted according to
the procedure described by Bligh and Dyer [18]. Brieﬂy, 109 M. pul-
monis cells were used to obtain membrane lipids and chloro-
form:methanol (1:2 by vol.) was used as the extractant.
Membrane lipids were separated using HPTLC silica gel 60 plates
(Merck, 105631), after which they were developed at room tem-
perature by a two-dimensional system using chloroform:metha-
nol:ammonia (65:35:4 by vol.) for the ﬁrst dimension and
chloroform:methanol:acetic acid:water (85:25:5:4 by vol.) for the
second dimension. Lipids spots were detected by 10% (v/v) H2SO4
and identiﬁed by comparison with those of standard lipids.
2.6. Preparation of liposome and calcein leakage assay
The lipid vesicles were prepared and the calcein leakage assay
was performed according to the procedure described previously
[19]. Calcein-entrapped vesicles were obtained by elution with
10 mM Tris buffer (pH 7.4) containing 150 mM NaCl on a Sephadex
G-50 column. In the calcein leakage assay, the ﬂuorescence inten-
sity was measured using a ﬂuorometer (VARIAN, USA) with excita-
tion and emission values of 490 and 520 nm, respectively. The
percent dye-release was evaluated by the following equation: leak-
age (%) = (F  F0)/(Fmax  F0)  100, where F0 was the ﬂuorescence
intensity of the control vesicle, and F and Fmax were the ﬂuores-
cence intensities achieved by peptides and 1% (v/v) Triton X-100,
respectively.
2.7. Anti-mycoplasma assay
The MICs of four AMPs and kanamycin were determined via a
broth dilution assay conducted in accordance with recommenda-
tions of the Clinical and Laboratory Standard Institute [20]. Brieﬂy,
mycoplasma cultures were diluted in fresh growth medium to a ﬁ-
nal concentration of 2  105 CFU/ml. Each peptide and kanamycin
were then prepared in acidiﬁed water (0.01% acetic acid) at 640 lg/
ml, after which the samples serially diluted 2-fold in acidiﬁed
water to 10 lg/ml. Next, 100 ll aliquots of mycoplasma were dis-
pensed into each well of a 96-well microtiter plate (Costar 3790,
Corning), after which 11 ll of sample solution were added and ad-
justed to a total assay volume of 111 ll. A change in the color of the
growth media containing phenol red as a pH indicator was moni-
tored to observe mycoplasma growth. The MIC was deﬁned as
the lowest concentration that completely inhibited the growth.
To verify the effects of POPC or POPG on the antibacterial activity
of the four AMPs against Escherichia coli, a radial diffusion assay
was conducted as previously described [21]. Brieﬂy, each peptide
was mixed with phospholipid liposome without calcein (peptide:
POPC, 1:40 by wt; peptide: POPG, 1:10 by wt) and incubated for
30 min at 37 C, after which 5 ll aliquots of the sample mixture
were subjected to radial diffusion assay. For the colony count as-
say, each peptide at a concentration corresponding to the MIC va-
lue was mixed with POPC or POPG liposome at the same ratio as in
the case of the radial diffusion assay. The total volume of peptide
and liposome was 50 ll. After incubation for 30 min at 37 C,
50 ll aliquots of cells (1  106 CFU) were added to the sample.
Table 1
MICs of AMPs and kanamycin against three M. pulmonis strains.
Agents MICs (lg/ml)
M. pulmonis
CT CTG1701 CTG2028
HG1 16 16 16
LL-37 32 32 32
MSI-78 64 64 64
Polymyxin B >64 >64 >64
Kanamycin 2 2 2
Fig. 2. PI uptake of M. pulmonis after treatment of four AMPs and kanamycin. 100%
uptake of PI was determined by treated with Triton X-100. The data represented
mean values of three independent experiments. Bars represented the standard
errors of the means.
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which 50 ll aliquots of the sample mixture were plated, either di-
rectly or after dilution, on PPLO agar. After 7 days of incubation at
30 C in a humid chamber, the resultant viable colonies were
counted. The data were expressed as the survival % of the test sam-
ple relative to the control sample that was not treated with
peptides.
3. Results
3.1. Anti-mycoplasma activity of AMPs
To evaluate the anti-mycoplasma activities of AMPs, we deter-
mined the MIC values of four AMPs and kanamycin against M. pul-
monis CT and its two mutant strains (CTG1701 and CTG2028). As
shown in Table 1, the MICs of three AMPs (HG1, LL-37 and MSI-
78) ranged from 16 to 64 lg/ml. Speciﬁcally, the following order
of decreasing activities was observed: HG1 > LL-37 > MSI-78. Poly-
myxin B was not found to exert anti-mycoplasma activity, even at
the highest concentration investigated in our experiment. The anti-
mycoplasma activity of three AMPs was also observed under SEM
at 30 min after treatment of M. pulmonis CT with AMPs at the
MIC of each peptide. Fig. 1 shows M. pulmonis treated with HG1
as a representative as other two samples were very similar. The cell
surface of M. pulmonis revealed dramatic alterations including sur-
face roughening and disruption within 30 min of exposure to
AMPs. In contrast, after treatment for 3 h with kanamycin, which
is known to have antibiotic activity against mycoplasmas, the
membrane ofM. pulmonismaintained its integrity as in the control
sample. Therefore, we concluded that substantial modiﬁcation of
the mycoplasma membrane should constitute a critical step in
the anti-mycoplasma effects of cationic AMPs. In a subsequent
experiment, we investigated the uptake of PI by mycoplasma cells
in a time dependent manner after treatment with four AMPs and
kanamycin at 16 lg/ml. As shown in Fig. 2, the PI uptake was sat-
urated within 3 min of treatment with the three AMPs. The maxi-
mum PI uptake induced by treatment with the AMPs occurred in
the same order as in the anti-mycoplasma activity of the AMPsFig. 1. Scanning electron micrographs ofM. pulmonis treated with HG1 or kanamycin. Kan
contrast, the M. pulmonis cells treated with HG1 revealed surface roughening and disrupindicated in Table 1. In addition, polymyxin B and kanamycin did
not induce uptake of PI by M. pulmonis. These results strongly sup-
ported our conclusion that the anti-mycoplasma activity of AMPs,
unlike antibiotics such as kanamycin, resulted from its physical at-
tack on the mycoplasma membrane.
3.2. Membrane lipids of M. pulmonis and AMP-induced calcein leakage
from liposomes
The membrane lipids of M. pulmonis were extracted from the
mixture of chloroform and methanol and subjected to two-
dimensional TLC (Fig. 3). The results indicated that the membrane
of M. pulmonis consists of ﬁve major types of lipids, neutral lipids,
PC, PG, CL and SPM. This membrane lipid proﬁle of M. pulmonis
was found to be similar to that of M. hyorhinis reported in a pre-
vious study [22]. We also prepared four types of calcein-en-
trapped liposomes consisting of PC, PG, CL and SPM and
employed them to evaluate the interaction between AMP and
each phospholipid. As shown in Fig. 4, AMPs induced leakage of
calcein from the POPC liposome in the following order:
HG1 > LL-37 > MSI-78 > polymyxin B. It should be noted that the
calcein leakage from the POPC vesicle by AMPs was in accordance
with the anti-mycoplasma activity of AMPs (Table 1) and the PI
uptake by M. pulmonis treated with AMPs (Fig. 2). Conversely,
all four AMPs induced calcein leakage from the POPG liposome
fairly well, although the order was different from that observed
for the POPC liposome. In contrast, when liposomes consisting
of CL or SPM were treated with AMPs, little or no calcein leakageamycin-treated sample showed a smooth surface as in the case of control sample. In
tion. Bar = 0.2 lm.
Fig. 3. The major polar lipids of M. pulmonis CT. The spots were tentatively
identiﬁed based on their comigration with commercial standards as NL, neutral
lipids; CL, cardiolipin; PG, phosphatidylglycerol; PC, phosphatidylcholine; SPM,
sphingomyelin.
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phospholipids such as CL and SPM.
3.3. Effect of membrane phospholipids on antimicrobial activity of
AMPs
We reasoned that the binding of AMPs to PC and/or PG might be
a critical step for their anti-mycoplasma activity. To verify our
assumption, the anti-E. coli activity of the four AMPs was tested
in the presence of POPC or POPG liposomes in a radial diffusion as-
say (Fig. 5A). All AMPs lost their anti-E. coli activity after incubation
with POPG liposomes. In addition, when AMPs were incubated
with POPC liposomes, the anti-E. coli activity of HG1 and LL-37 dis-
appeared and the activity of MSI-78 signiﬁcantly decreased. In the
case of polymyxin B, its anti-E. coli activity was not affected by
POPC liposomes, suggesting polymyxin B did not bind to PC.
To further conﬁrm the effects of PC and PG on the anti-myco-
plasma activity of AMPs, we performed a colony count assay withFig. 4. Leakage percent from the liposomes consisting of POPC, POPG, CL or SPM. The ma
treated with Triton X-100. The zero level corresponded to liposomes ﬂuorescence in
experiments. Bars represented the standard errors of the means.HG1, LL-37 and MSI-78 (Fig. 5B). Polymyxin B was not used in this
experiment since it had no anti-mycoplasma activity. As a result,
the anti-mycoplasma activity of HG1 and LL-37 was abolished in
the presence of POPC or POPG. In the case of MSI-78, while its
anti-mycoplasma activity was completely attenuated after incuba-
tion with POPG, it was relatively unchanged following treatment
with POPC. When combined with the data presented in Figs. 4
and 5, these results indicate that binding of AMPs to PC of the
mycoplasma membrane phospholipids might be critical to their
anti-mycoplasma activity, but that the afﬁnity of AMPs for PG
might not be relevant to this activity since polymyxin B with no
anti-mycoplasma activity also showed a strong afﬁnity for PG.
4. Discussion
This study was conducted to elucidate the mode of action for
the anti-mycoplasma activity of cationic AMPs, which have been
shown to exert potent antimicrobial activity against a broad range
of microorganisms including Gram (+) and () bacteria and fungi.
Among the well-known AMPs that are found in nature, magainin,
cecropin, and defensin have attracted a great deal of attention as
promising candidates for novel antibiotics owing to their broad
antimicrobial spectrum as well as their mode of action, which is
distinctly different from that of conventional antibiotics. However,
they have also been found to have a wide disparity in their antimi-
crobial activities against mycoplasmas and wall-covered bacteria.
While peptides have potent antibacterial activity against bacteria
equipped with cell wall [8], they have little or no anti-mycoplasma
activity against a variety of mycoplasmas that belong to the class
Mollicutes [1]. In contrast, we found that AMPs such as LL-37 and
a derivative of halocidin (HG1), which are found in humans and
the tunicates, respectively, were active in killing of both bacteria
and M. pulmonis. Therefore, it was assumed that AMPs might re-
quire for a distinct option to exert their anti-mycoplasma activity.
Many studies have demonstrated that the action mechanism of
AMPs against microbes involves their binding of microbes via spe-
ciﬁc binding to cell wall components and subsequent destruction
of the microbes by causing physical damage to the plasma mem-
brane [8,9]. However, it is still obscure how AMPs kill mycoplas-
mas that are not equipped with binding targets found in the
microbial cell wall. Evaluation of the data presented in Figs. 1
and 2 revealed that HG1, LL-37 and MSI-78 were capable of killing
M. pulmonis by causing signiﬁcant damage to the integrity of the
plasmamembrane upon treatment with AMPs at each MIC. The cellximum level of ﬂuorescence (100%) was determined by complete lysis of liposomes
the absence of peptide. The data represented mean values of three independent
Fig. 5. Effects of POPC or POPG liposomes on the anti-E. coli or anti-mycoplasma
activity of AMPs. (A) The mixtures of AMPs with liposomes were introduced into the
wells of radial diffusion assay plates seeded with E. coli. (B) After 30 min incubation
of AMPs with liposomes, their anti-mycoplasma activity was evaluated in colony
count assay. The Mann–Whitney U test was performed by comparing the results for
each test group with the value for survival in buffer (⁄P < 0.05; ⁄⁄P < 0.01).
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layer composed of glucose, galactose and N-acetylglucosamine
[17]. Thus, it is tempting to infer that the anti-mycoplasma activity
of AMPs may be hindered by this layer. However, as shown in Ta-
ble 1, AMPs tested in this study were conﬁrmed to have constant
MIC values against the wild type and EPS mutants of M. pulmonis.
Furthermore, since cationic AMPs diffuse freely in agarose gels,
which have a low sieving effect, it is not likely that the neutral (un-
charged) EPS layer contributes to protection of the mycoplasma
against AMPs. Overall, the results of this study indicated that the
surface layer of mycoplasma did not affect the anti-mycoplasma
activity of AMPs. This conclusion allowed us to assume that cat-
ionic AMPs might directly contact the mycoplasma membrane
and that the anti-mycoplasma activity of AMPs depends on their
afﬁnity to membrane phosopholipids.
Unlike cell wall synthesizing bacteria, mycoplasmas incorporate
exogenous lipids (mainly PC and SPM) from the growth medium
[3]. In addition, they synthesize the acidic phospholipids PG and
CL, similar to other bacteria [4]. Accordingly, the phospholipids
of the mycoplasma membrane normally consist of exogenous lip-
ids (PC and SPM) and de novo synthesized lipids (PG and CL),
which was observed in this study (Fig. 3). Naturally, the polar head
occurring in the outer leaﬂet of the membrane lipid bilayer would
be a primary target for AMPs to recognize mycoplasmas. The re-
sults of the present study revealed that the four AMPs tested bind
PC with afﬁnities proportional to their anti-mycoplasma activity,although they all tend to strongly bind PG. Moreover, the binding
afﬁnity of AMPs for PC rather than PG of mycoplasma membrane
lipids was shown to be critical for their anti-mycoplasma activity.
It has been reported that exogenous choline-containing PC and
SPM, which are very uncommon lipids in wall-covered bacteria,
were ﬁrst incorporated into the outer leaﬂet of the mycoplasma
membrane bilayer, then translocated to the inner leaﬂet or accu-
mulated in the outer half [4]. Accordingly, it is highly probable that
exogenous lipids such as PC and SPM are preferentially distributed
in the outer half of the mycoplasma membrane and that de novo
synthesized PG are primarily located in the inner leaﬂet since the
outer leaﬂet would be continuously replenished with phospholip-
ids from the growth medium. This unequal distribution of PC and
PG in the mycoplasmamembrane bilayer accounts for the disparity
between antibacterial and anti-mycoplasma activity of AMPs. Spe-
ciﬁcally, in order to exert anti-mycoplasma activity, AMPs should
directly bind the plasma membrane lipid bilayer since mycoplas-
mas do not have a cell wall component that can be recognized
by AMPs. Therefore, it was determined that the afﬁnity of AMPs
for phospholipids in the outer leaﬂet is important for their anti-
mycoplasma activity.
In conclusion, we demonstrated that causing substantial dam-
age to the integrity of the plasma membrane is a critical step for
the anti-mycoplasma activity of AMPs as did most AMPs against
wall-covered bacteria. The anti-mycoplasma activity of AMPs
mainly depends on their binding afﬁnity for PC occurring in the
plasma membrane. It is well known that most mycoplasmas
strictly require choline-containing lipids for growth and obtain
them from the growth medium. This unique property of mycoplas-
mas has led them to have a different susceptibility to AMPs.Acknowledgments
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